Compare Cassava Sciences Inc (FLNA) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ulta Beauty Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Ulta Beauty Inc trades at $478.84 (market cap $20.04B). The key difference: Ulta Beauty Inc is far larger — about 377.1× Cassava Sciences Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | ULTA | |
|---|---|---|
Market Cap | $53.14M | $20.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $706.82 |
52-Week Low | $1.09 | $450.75 |
Enterprise Value | -$33.43M | $22.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
ULTA Beauty trades at $469.12, down 0.89% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 39.33% gross margin and 47.45% ROE, though revenue growth has moderated. Recent news highlights international expansion and a new CTO appointment, while analyst consensus remains bullish with a $623.73 price target.
Outlook: ULTA presents a value opportunity with solid fundamentals and market share gains, but faces risks from consumer demand volatility and competitive pressures. Wall Street's strong buy ratings suggest upside potential, though investors should monitor margin trends and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
